<Disease><Name>ADRENOLEUKODYSTROPHY, X-LINKED</Name><Synonym>ADDISON DISEASE AND CEREBRAL SCLEROSIS; ADRENOLEUKODYSTROPHY, X-LINKED; ADDISON DISEASE AND CEREBRAL SCLEROSIS</Synonym><OMIM><Number>300100</Number><URL>http://omim.org/entry/300100</URL></OMIM><Orphanet><Number>43</Number><URL>http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&amp;Expert=43</URL></Orphanet><Protein><Number>ATP-binding cassette sub-family D member 1</Number><URL>http://www.uniprot.org/uniprot/P33897</URL></Protein><ExPASy><Number /><URL /></ExPASy><Gene>Xp28</Gene><ICD>E71.3</ICD><Summary>rare (1:17000) ;X-linked recessive;USA: 1:42,000 (hemizygotes), 1:16,800 (hemizygotes plus heterozygotes) [Bezman et al. 2001] X-linked therapy: diet with Lorenzos oil - glycerol trioleate - glyceryl trierucate oil bone marrow transplantation (experimental)</Summary><Symptoms><symtomp><id>2435</id><symptom>adrenal insufficiency</symptom><category>ENDOCRINE SYSTEM | GASTROINTESTINAL SYSTEM</category></symtomp><symtomp><id>1942</id><symptom>ataxia</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>2323</id><symptom>behavior, abnormal or bizarre, confusion / behaviour, abnormal or bizarre</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>1955</id><symptom>behavior, hyperactive, restless / behaviour, hyperactive, restless</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>2211</id><symptom>blindness, visual loss, visual impairment</symptom><category>EYES | NERVOUS SYSTEM</category></symtomp><symtomp><id>2164</id><symptom>dysarthria</symptom><category>NERVOUS SYSTEM | NERVOUS SYSTEM</category></symtomp><symtomp><id>2163</id><symptom>dysphagia</symptom><category>GASTROINTESTINAL SYSTEM | GASTROINTESTINAL SYSTEM</category></symtomp><symtomp><id>3709</id><symptom>epilepsy</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>2161</id><symptom>eye defect beginning in infancy or childhood</symptom><category>EYES | GENERAL TOPICS</category></symtomp><symtomp><id>2169</id><symptom>hyperpigmentation</symptom><category>SKIN</category></symtomp><symtomp><id>3843</id><symptom>leukodystrophy</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>2213</id><symptom>MRI, brain, abnormalities [-]</symptom><category>LABORATORY FINDINGS | NERVOUS SYSTEM</category></symtomp><symtomp><id>1917</id><symptom>neurological deterioration / neurologic deterioration</symptom><category>GENERAL TOPICS | NERVOUS SYSTEM</category></symtomp><symtomp><id>1915</id><symptom>onset, adulthood / adoulthood</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>2507</id><symptom>onset, childhood / childhood</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>1943</id><symptom>seizures</symptom><category>NERVOUS SYSTEM | NERVOUS SYSTEM</category></symtomp><symtomp><id>1974</id><symptom>spastic diplegia/quadriplegia/tetraplegia</symptom><category>NERVOUS SYSTEM | NERVOUS SYSTEM</category></symtomp></Symptoms><Metabolites><metabolite><id>438</id><name>C24:0/C22:0</name><specimen>plasma</specimen><value>increased</value><min>0.50</min><max>0.90</max><unit>no unit</unit><age>no data</age><method /><comment /></metabolite><metabolite><id>437</id><name>C26:0</name><specimen>plasma</specimen><value>increased</value><min>0.45</min><max>1.32</max><unit>&#956;mol/l</unit><age>no data</age><method /><comment /></metabolite><metabolite><id>786</id><name>C26:0</name><specimen>cerebrospinal fluid</specimen><value>increased</value><min>0.00</min><max>0.06</max><unit>&#956;g/ml</unit><age>no data</age><method /><comment /></metabolite><metabolite><id>838</id><name>C26:0</name><specimen>fibroblasts</specimen><value>increased</value><min>0.05</min><max>0.21</max><unit>&#181;g/mg</unit><age>no data</age><method /><comment /></metabolite><metabolite><id>484</id><name>C26:0/C22:0</name><specimen>plasma</specimen><value>increased</value><min>0.01</min><max>0.02</max><unit>no unit</unit><age>no data</age><method /><comment /></metabolite><metabolite><id>839</id><name>C26:0/C22:0</name><specimen>fibroblasts</specimen><value>increased</value><min>0.02</min><max>0.13</max><unit>no unit</unit><age>no data</age><method /><comment /></metabolite><metabolite><id>439</id><name>Hexacosenoic acid C26:1</name><specimen>plasma</specimen><value>increased</value><min>0.02</min><max>0.51</max><unit>&#181;g/ml</unit><age>no data</age><method /><comment /></metabolite><metabolite><id>787</id><name>Hexacosenoic acid C26:1</name><specimen>cerebrospinal fluid</specimen><value>increased</value><min>0.00</min><max>0.00</max><unit>&#956;g/ml</unit><age>no data</age><method /><comment /></metabolite><metabolite><id>433</id><name>Pipecolic acid</name><specimen>urine</specimen><value>increased</value><min>0.50</min><max>35.00</max><unit>mmol/mol creatinine</unit><age>infancy</age><method>GCMS</method><comment /></metabolite><metabolite><id>435</id><name>Pipecolic acid</name><specimen>urine</specimen><value>increased</value><min>0.10</min><max>3.50</max><unit>mmol/mol creatinine</unit><age>Childhood</age><method>GCMS</method><comment /></metabolite><metabolite><id>2036</id><name>Pipecolic acid</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>0.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method>NMR</method><comment>Bruker 2018</comment></metabolite><metabolite><id>428</id><name>Pipecolic acid</name><specimen>plasma</specimen><value>increased</value><min>0.80</min><max>5.30</max><unit>&#181;mol/l</unit><age>newborn</age><method /><comment /></metabolite><metabolite><id>429</id><name>Pipecolic acid</name><specimen>plasma</specimen><value>increased</value><min>0.50</min><max>3.80</max><unit>&#181;mol/l</unit><age>infant</age><method /><comment /></metabolite><metabolite><id>430</id><name>Pipecolic acid</name><specimen>plasma</specimen><value>increased</value><min>0.40</min><max>4.90</max><unit>&#181;mol/l</unit><age>child</age><method /><comment /></metabolite><metabolite><id>431</id><name>Pipecolic acid</name><specimen>plasma</specimen><value>increased</value><min>0.70</min><max>2.60</max><unit>&#181;mol/l</unit><age>&gt;5 years</age><method /><comment /></metabolite><metabolite><id>432</id><name>Pipecolic acid</name><specimen>urine</specimen><value>increased</value><min>13.90</min><max>44.70</max><unit>&#181;mol/g creatinine</unit><age>newborn</age><method /><comment /></metabolite><metabolite><id>434</id><name>Pipecolic acid</name><specimen>urine</specimen><value>increased</value><min>1.60</min><max>13.40</max><unit>&#181;mol/g creatinine</unit><age>child</age><method /><comment /></metabolite></Metabolites><Literatures><literature><id>3629</id><title>Adult-onset cerebello-brainstem dominant form of X-linked adrenoleukodystrophy presenting as multiple system atrophy: case report and literature review.</title><author>Ogaki K,</author><journal>Neuropathology</journal><year>2016</year><book /><volume>36</volume><number>1</number><pages>64-76</pages><co_aut>et al.</co_aut></literature><literature><id>3630</id><title>Novel Therapeutic Targets and Drug Candidates for Modifying Disease Progression in Adrenoleukodystrophy.</title><author>Pujol A</author><journal>Endocr Dev</journal><year>2016</year><book /><volume>30</volume><number>0</number><pages>147-160</pages><co_aut /></literature><literature><id>3631</id><title>Clinical, biochemical, neuroimaging and molecular findings of X-linked Adrenoleukodystrophy patients in South China</title><author>Jiang MY,</author><journal>Metab Brain Dis</journal><year>2015</year><book /><volume>30</volume><number>6</number><pages>1439-1444</pages><co_aut>et al.</co_aut></literature><literature><id>3632</id><title>Oxidative stress, mitochondrial and proteostasis malfunction in adrenoleukodystrophy: A paradigm for axonal degeneration</title><author>Fourcade S,</author><journal>Free Radic Biol Med</journal><year>2015</year><book /><volume>88</volume><number>0</number><pages>18-29</pages><co_aut>Ferrer I, Pujol A</co_aut></literature><literature><id>3633</id><title>A clinical approach to the diagnosis of patients with leukodystrophies and genetic leukoencephelopathies</title><author>Parikh S,</author><journal>Mol Genet Metab</journal><year>2015</year><book /><volume>114</volume><number>4</number><pages>501-515</pages><co_aut>et al.</co_aut></literature><literature><id>3634</id><title>The genetic landscape of X-linked adrenoleukodystrophy: inheritance, mutations, modifier genes, and diagnosis</title><author>Wiesinger C,</author><journal>Appl Clin Genet</journal><year>2015</year><book /><volume>8</volume><number>0</number><pages>109-121</pages><co_aut>Eichler FS, Berger J</co_aut></literature><literature><id>3153</id><title>X-linked adrenoleukodystrophy: Clinical, metabolic, genetic and pathophysiological aspects</title><author>Kemp S,</author><journal>Biochim Biophys Acta</journal><year>2012</year><book /><volume>1822</volume><number>9</number><pages>1465-1474</pages><co_aut>Berger J, Aubourg P</co_aut></literature><literature><id>3154</id><title>Leukodystrophies</title><author>Perlman SJ,</author><journal>Adv Exp Med Biol</journal><year>2012</year><book /><volume>724</volume><number>0</number><pages>154-171</pages><co_aut>Mar S</co_aut></literature><literature><id>2855</id><title>Newborn screening for X-linked adrenoleukodystrophy (X-ALD): validation of a combined liquid chromatography-tandem mass spectro</title><author>Hubbard WC</author><journal>Mol Genet Metab</journal><year>2009</year><book /><volume>97</volume><number>3</number><pages>312-320</pages><co_aut>et al.</co_aut></literature><literature><id>2856</id><title>Leukoencephalopathy in adults: Is it adrenoleukodystrophy? A case report and molecular analysis</title><author>Dohle CI</author><journal>J Neurol Sci</journal><year>2009</year><book /><volume>0</volume><number>0</number><pages /><co_aut>et al.</co_aut></literature><literature><id>1592</id><title>X-linked adrenoleukodystrophy (ALD)</title><author>Imamura A</author><journal>Nippon Rinsho</journal><year>2004</year><book /><volume>62</volume><number>0</number><pages>389-392</pages><co_aut>Suzuki Y</co_aut></literature><literature><id>1593</id><title>X-linked adrenoleukodystrophy ABCD1 gene mutation analysis in China</title><author>Pan H</author><journal>Zhonghua Yi Xue Yi Chuan Xue Za Zhi</journal><year>2004</year><book /><volume>21</volume><number>1</number><pages>1-4</pages><co_aut>et al.</co_aut></literature><literature><id>1595</id><title>Evidence that oxidative stress is increased in patients with X-linked adrenoleukodystrophy</title><author>Vargas CR</author><journal>Biochim Biophys Acta</journal><year>2004</year><book /><volume>1688</volume><number>1</number><pages>26-32</pages><co_aut>et al.</co_aut></literature><literature><id>1597</id><title>Free radical release in C6 glial cells enriched in hexacosanoic acid: implication for X-linked adrenoleukodystrophy pathogenesi</title><author>Di Biase A</author><journal>Neurochem Int</journal><year>2004</year><book /><volume>44</volume><number>4</number><pages>215-221</pages><co_aut>et al.</co_aut></literature><literature><id>1415</id><title>Pharmacological induction of redundant genes for a therapy of X-ALD: phenylbutyrate and other compounds</title><author>Bugaut M</author><journal>Adv Exp Med Biol</journal><year>2003</year><book /><volume>544</volume><number>0</number><pages>281-291</pages><co_aut>et al.</co_aut></literature><literature><id>1416</id><title>Evaluation of the preventive effect of glyceryl trioleate-trierucate (Lorenzos oil) therapy in X-linked adrenoleukodystrophy: r</title><author>Moser HW</author><journal>Adv Exp Med Biol</journal><year>2003</year><book /><volume>544</volume><number>0</number><pages>369-387</pages><co_aut>et al.</co_aut></literature><literature><id>1417</id><title>Biochemical effect of intravenous arginine butyrate in X-linked adrenoleukodystrophy</title><author>McGovern MM</author><journal>Pediatr</journal><year>2003</year><book /><volume>142</volume><number>6</number><pages>709-713</pages><co_aut>et al.</co_aut></literature><literature><id>1594</id><title>Clinical characteristics of X-linked adrenoleukodystrophy</title><author>Xiong H</author><journal>Zhonghua Er Ke Za Zhi</journal><year>2003</year><book /><volume>41</volume><number>3</number><pages>203-207</pages><co_aut>et al.</co_aut></literature><literature><id>1596</id><title>Single cell co-amplification of polymorphic markers for the indirect preimplantation genetic diagnosis of hemophilia A, X-linke</title><author>Gigarel N</author><journal>Hum Genet</journal><year>2003</year><book /><volume>114</volume><number>3</number><pages>298-305</pages><co_aut>et al.</co_aut></literature><literature><id>1598</id><title>Adult-onset dementia with prominent frontal lobe dysfunction in X-linked adrenoleukodystrophy with R152C mutation in ABCD1 gene</title><author>Larner AJ</author><journal>J Neurol</journal><year>2003</year><book /><volume>250</volume><number>10</number><pages>1253-1254</pages><co_aut /></literature><literature><id>1201</id><title>Intrathecal baclofen in X-linked adrenoleukodystrophy</title><author>Chu ML</author><journal>Pediatr Neurol</journal><year>2001</year><book /><volume>24</volume><number>0</number><pages>156-158</pages><co_aut>Sala DA, Weiner HL</co_aut></literature><literature><id>1202</id><title>The clinical course of childhood and adolescent adrenoleukodystrophy before and after Lorenzos oil</title><author>Suzuki Y</author><journal>Brain Dev</journal><year>2001</year><book /><volume>23</volume><number>0</number><pages>30-33</pages><co_aut>et al.</co_aut></literature><literature><id>1227</id><title>Adrenoleukodystrophy: incidence, new mutation rate, and results of extended family screening</title><author>Bezman L</author><journal>Ann Neurol</journal><year>2001</year><book /><volume>49</volume><number>4</number><pages>512-517</pages><co_aut>et al.</co_aut></literature><literature><id>1203</id><title>Lovastatin does not correct the accumulation of very long-chain fatty acids in tissues of adrenoleukodystrophy protein-deficien</title><author>Yamada T</author><journal>J Inherit Metab Dis 2000 Sep;23(6):607-14</journal><year>2000</year><book /><volume>23</volume><number>0</number><pages>607-614</pages><co_aut>et al.</co_aut></literature><literature><id>1414</id><title>Pharmacological induction of peroxisomes in peroxisome biogenesis disorders</title><author>Wei H</author><journal>Ann Neurol</journal><year>2000</year><book /><volume>47</volume><number>3</number><pages>286-296</pages><co_aut>et al.</co_aut></literature><literature><id>2638</id><title>Bone marrow transplantation for the treatment of X-linked adrenoleukodystrophy</title><author>Suzuki Y</author><journal>J Inherit Metab Dis</journal><year>2000</year><book /><volume>23</volume><number>5</number><pages>453-458</pages><co_aut>et al.</co_aut></literature><literature><id>901</id><title>Immunoablation does not delay the neurologic progression of X-linked adrenoleukodystrophy</title><author>Nowaczyk MJ</author><journal>J Pediatr</journal><year>1997</year><book /><volume>131</volume><number>0</number><pages>453-455</pages><co_aut>et al.</co_aut></literature><literature><id>638</id><title>Arrested cerebral adrenoleukodystrophy: a clinical and proton magnetic resonance spectroscopy study in three patients</title><author>Korenke GC</author><journal>Pediatr Neurol</journal><year>1996</year><book /><volume>15</volume><number>0</number><pages>103-107</pages><co_aut>et al.</co_aut></literature><literature><id>54</id><title>Adrenoleukodystrophy: natural history, treatment and outcome</title><author>Moser HW</author><journal>J Inherit Metab Dis</journal><year>1995</year><book /><volume>18</volume><number>0</number><pages>435-447</pages><co_aut /></literature><literature><id>57</id><title>The future for treatment by bone marrow transplantation for adrenoleukodystrophy, metachromatic leukodystrophy, globoid cell leu</title><author>Krivit W</author><journal>J Inherit Metab Dis</journal><year>1995</year><book /><volume>18</volume><number>0</number><pages>398-412</pages><co_aut>Lockman LA, Watkins PA, Hirsch J, Shapiro EG</co_aut></literature><literature><id>172</id><title>X-linked adrenoleukodystrophy</title><author>Moser HW</author><journal>The metabolic and molecular bases of inherited disease, 7/e; Editors: C.R.Scriver, A.L.Beaudet, W.S.Sly, D.Valle; McGraw-Hill Inc.</journal><year>1995</year><book /><volume>2</volume><number>72</number><pages>2325-2349</pages><co_aut>Smoth KD, Moser AB</co_aut></literature><literature><id>210</id><title>DNA diagnosis of X-linked adrenoleukodystrophy</title><author>Seneca S</author><journal>J Inher Met Dis Suppl.</journal><year>1995</year><book /><volume>18</volume><number>0</number><pages>34-44</pages><co_aut>Lissens W</co_aut></literature><literature><id>227</id><title>Measurement of dihydroxyacetone-phosphate acyltransferase (DHAPAT) in chorionic villous samples, blood cells and cultured cells&lt;</title><author>Wanders RJA</author><journal>J Inher Met Dis Suppl.</journal><year>1995</year><book /><volume>18</volume><number>0</number><pages>90-99</pages><co_aut>et al.</co_aut></literature><literature><id>229</id><title>Peroxisomal disorders</title><author>Heymans HS</author><journal>J Inherit Metab Dis</journal><year>1995</year><book /><volume>0</volume><number>0</number><pages>421-433</pages><co_aut>Wanders RJA, Schutgens RBH</co_aut></literature><literature><id>6</id><title>Measurement of Plasma Very Long-Chain Fatty Acids as a Preliminary Screening Procedure for the Diagnosis of Peroxysomal Disorder</title><author>Steinberg SJ</author><journal>J Inher Metab Dis</journal><year>1994</year><book /><volume>17</volume><number>0</number><pages>323-326</pages><co_aut>Fensom AH, Dalton NR, Toseland PA, Kennedy CR, Mowat AP</co_aut></literature><literature><id>231</id><title>Clinical and biochemical characteristics of peroxisomal disorders: un update</title><author>Wanders RJA</author><journal>Eur J Pediatr Suppl</journal><year>1994</year><book /><volume>153</volume><number>0</number><pages>S44-S48</pages><co_aut>Barth PG, Schutgens RBH, Tager JM</co_aut></literature><literature><id>471</id><title>[Dietary treatment of adrenoleukodystrophy. Preliminary results of a long-term study]</title><author>Theda Ch</author><journal>Monatschr Kinderheilk</journal><year>1994</year><book /><volume>142</volume><number>0</number><pages>850-856</pages><co_aut>K&#246;hler W, Moser A, Moser H</co_aut></literature><literature><id>51</id><title>Peroxysomal Disorders: Concentrations of metabolites in cerebrospinal fluid compared wth plasma</title><author>Ten Brink HJ</author><journal>J Inherit Metab Dis</journal><year>1993</year><book /><volume>16</volume><number>0</number><pages>587-589</pages><co_aut>van den Heuvel CMM, Poll-The BT, Wanders RJA, Jacobs C</co_aut></literature></Literatures></Disease>